Xin Guan, Chaoran Zhang, Peng Hu, Zefeng Yang, Jinping Zhang, Yunlian Zou, Yan Wen, Huiyuan Li, Tonghua Yang, Renbin Zhao, Zengzheng Li
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are the standard therapy for patients with chronic myeloid leukemia (CML). While their use greatly increases patient survival rates and can lead to normal life expectancy, bacterial infections in the lungs continue to play a significant role in determining patient outcomes. METHODS: In this study, the medical records of 272 CML and 53 healthy adults were analyzed. Information on age, sex, body temperature, procalcitonin (PCT), C-reactive protein (CRP), and cytokine levels were collected from patients...
2023: Journal of Oncology